Monitoring virological responses to interferon-ribavirin and interferon monotherapy of chronic hepatitis C re-treated due to relapse or non-response

Scandinavian Journal of Infectious Diseases

Volumn 33, Issue 2, 2001, Pages 110-115

  Westin, J ^a   Lindh, M ^a   Nenonen, N ^a   Lagging, L M ^a   Norkrans, G ^a   Wejstal R ^a  

^a SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

INTERFERON; RIBAVIRIN; VIRUS RNA;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG MONITORING; DRUG RESPONSE; FEMALE; GENOTYPE; HEPATITIS C; HUMAN; LONG TERM CARE; MALE; MONITOR; MONOTHERAPY; RELAPSE; SHORT COURSE THERAPY; TREATMENT OUTCOME; VIREMIA;

ADULT; ANTIVIRAL AGENTS; DRUG THERAPY, COMBINATION; FEMALE; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INTERFERONS; MALE; MIDDLE AGED; RECURRENCE; RIBAVIRIN; RNA, VIRAL; TREATMENT FAILURE; VIRAL LOAD; VIREMIA;

EID: 0035112923     PISSN: 00365548     EISSN: None     Source Type: Journal    
DOI: 10.1080/003655401750065481     Document Type: Article

References (36)

1. Treatment of chronic hepatitis C with recombinant interferon alfa. A multicenter randomized, controlled trial
2. Meta-analysis of interferon randomized trials in the treatment of viral hepatitis C: Effects of dose and duration
3. Therapy of hepatitis C: Meta-analysis of interferon alfa-ab trials
4. Long-term efficacy of ribavirin plus interferon alfa in the treatment of chronic hepatitis C
5. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C
6. Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus
7. Randomised, double-blind, placebo-controlled trial of interferon alpha-2b with and without ribavirin for chronic hepatitis C
8. Interferon-ribavirin for chronic hepatitis C with and without cirrhosis: Analysis of individual patient data of six controlled trials
9. Interferon alfa-2b alone or in combination with ribavirin for the treatment or relapse of chronic hepatitis C
10. Interferon-alpha-2B and ribavirin in combination for chronic hepatitis C patients not responding to interferon-alpha alone: An Italian multicenter, randomized, controlled, clinical study
11. A pilot study of ribavirin therapy for chronic hepatitis C
12. Ribavirin in the treatment of chronic hepatitis C unresponsive to alfa interferon
13. Ribavirin treatment for patients with chronic hepatitis C: Results of a placebo-controlled study
14. Ribavirin monotherapy in patients with chronic hepatitis C: A retrospective study of 95 patients
15. Hepatitis C virus dynamics in vivo: Effect of ribavirin and interferon alfa on viral turnover
16. Genotyping of hepatitis C virus isolates by a modified polymerase chain reaction assay using type specific primers: Epidemiological application
17. Combination antiviral therapy with ribavirin and interferon alfa in interferon alfa relapsers and non-responders: Italian experience
18. Combined treatment with interferon alpha-2b and ribavirin for chronic hepatitis C in patients with a previous non-response or non-sustained response to interferon alone
19. Sequential versus concomitant administration of ribavirin and initerferon alfa-n3 in patients with chronic hepatitis C not responding to interferon alone: Results of a randomized, controlled trial
20. Interferon-alpha ribavirin in chronic hepatitis C resistant to previous interferon-alpha course: Results of a randomized multicenter trial
21. Ribavirin and interferon alfa-2b in chronic hepatitis C: Assessment of possible pharmacokinetic and pharmacodynamic interactions
22. Correlation of serum HCV RNA and alanine aminotransferase levels in chronic hepatitis C patients during treatment with ribavirin
23. Early hepatitis C virus-RNA response predict interferon treatment outcomes in chronic hepatitis C
24. The antiviral compound ribavirin modulates the T helper (Th) 1/Th2 subset balance in hepatitis B and C virus-specific immune responses
25. Effects of the ribavirin-interferon alpha combination on cultured peripheral blood mononuclear cells from chronic hepatitis C patients
26. Ribavirin polarizes human T cell responses towards a Type 1 cytokine profile
27. Loss of serum HCV RNA at week 4 of interferon-alpha therapy is associated with more favorable long-term response in patients with chronic hepatitis C
28. Baseline level and early suppression of serum HCV RNA for predicting sustained complete response to alpha-interferon therapy
29. Is there an optimal time to measure quantitative HCV RNA to predict nonresponse following interferon treatment for chronic HCV infection?
30. Quantification of the initial decline of serum hepatitis C virus RNA and response to interferon alfa
31. Discrepancy between biochemical and virological responses to interferonalpha in chronic hepatitis C
32. Relationship between biochemical and virological responses to interferon therapy in chronic hepatitis C infection
33. Early prediction of response in interferon monotherapy and in interferon-ribavirin combination therapy for chronic hepatitis C: HCV RNA at 4 weeks versus ALT
34. Factors useful in predicting the response to interferon therapy in chronic hepatitis C
35. Pretreatment serum hepatitis C virus RNA levels and hepatitis C virus genotype are the main and independent prognostic factors of sustained response to interferon alfa therapy in chronic hepatitis C
36. Dose-dependent acute clearance of hepatitis C genotype 1 virus with interferon alfa